Doripenem
From Wikipedia, the free encyclopedia
 |
|
|
Doripenem
|
|
| Systematic (IUPAC) name | |
| (4R,5S,6S)-6-(1-hydroxyethyl)-4-methyl-7-oxo-3- [(3S,5S)-5-[(sulfamoylamino)methyl]pyrrolidin-3-yl] sulfanyl-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C15H24N4O6S2 |
| Mol. mass | 420.50426 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Renal |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
? |
| Legal status | |
| Routes | IM, IV |
Doripenem is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It was launched by Shionogi Co. of Japan under the brand name Finibax in 2005. It is particularly active against Pseudomonas aeruginosa.
Doripenem was approved by the United States Food and Drug Administration on October 12, 2007, to be sold under the tradename Doribax.[1]
[edit] References
- ^ U.S. Food and Drug Administration (October 17, 2007). "FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal Infections". Press release. Retrieved on 2007-10-25.
|
||||||||||||||||||||
